SmartCella raises EUR 50 million to accelerate growth and commercialization
SmartCella Holding AB (“SmartCella”) today announces a new share issue raising approximately EUR 50 million to accelerate growth and support commercialization of the Extroducer and the company’s cell and mRNA operations. The share issue was supported by existing large institutional investors such as Fjärde AP-fonden, AMF Pension and SEB-Stiftelsen, as well as a new long-term strategic investor, AstraZeneca (committing to approximately half of the share issue) and the new larger institutional investors Handelsbanken Fonder and RoosGruppen AB, at a pre-money valuation of approximately EUR 500